According to Fortune Business Insights, the global Peptide Mapping Market was valued at USD 765.2 million in 2025 and is projected to grow from USD 834.5 million in 2026 to USD 1,668.8 million by 2034, exhibiting a CAGR of 9.05% during the forecast period (2026–2034). The increasing adoption of biologics, biosimilars, monoclonal antibodies, and advanced protein therapeutics is driving demand for peptide mapping technologies across pharmaceutical, biotechnology, and research laboratories.
Peptide mapping is a specialized analytical technique used to identify, characterize, and verify proteins by breaking them into smaller peptide fragments. The method is widely utilized in biologics characterization, quality control (QC), stability testing, biosimilar comparability studies, and regulatory submissions. Technologies such as LC-MS/MS, LC-MS, and HPLC-UV play a crucial role in ensuring product quality, sequence accuracy, and post-translational modification analysis.
The growing pipeline of biologic drugs, recombinant proteins, and monoclonal antibodies has significantly increased the need for reliable peptide mapping solutions. Pharmaceutical companies depend on peptide mapping to ensure product identity, consistency, and regulatory compliance throughout drug development.
Increasing investments in proteomics and protein characterization research are accelerating market growth. Research organizations require advanced peptide mapping technologies to study protein structures, biomarkers, and disease mechanisms with greater precision.
Modern LC-MS/MS platforms provide improved sensitivity, accuracy, and reproducibility. Their ability to identify post-translational modifications and impurities makes them essential for advanced biologics analysis.
Global regulatory agencies continue to emphasize comprehensive analytical characterization for biologics and biosimilars. This requirement encourages pharmaceutical manufacturers to invest in advanced peptide mapping workflows.
Artificial intelligence and laboratory automation are becoming major trends in peptide mapping. Automated sample preparation, AI-driven data interpretation, and workflow software reduce manual effort while improving accuracy and reproducibility.
Biopharmaceutical manufacturers are increasingly implementing Multi-Attribute Methods (MAM) that combine peptide mapping with mass spectrometry for simultaneous monitoring of multiple quality attributes during manufacturing.
Many pharmaceutical companies are outsourcing peptide mapping services to contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to reduce infrastructure costs and access specialized analytical expertise.